Monomorphic epitheliotropic intestinal T-cell lymphoma
Clinical trials for Monomorphic epitheliotropic intestinal T-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Monomorphic epitheliotropic intestinal T-cell lymphoma trials appear
Sign up with your email to follow new studies for Monomorphic epitheliotropic intestinal T-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo targets tough T-Cell lymphoma
Disease control PausedThis phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control PausedThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Lymphoma drug combo trial pulled before it started
Disease control CancelledThis study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase 2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC